Ascendis Pharma AS (MEX:ASND1N) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ASND1N Ascendis Pharma AS MEX:ASND1N
43 GF Score
Price MXN4,424.97
! 3 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS  (MEX:ASND1N) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ascendis Pharma AS Cyclically Adjusted PB Ratio Related Terms


Ascendis Pharma AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted PB Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:ASND1N vs JAZZ, BBIO, EXEL: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PB Ratio falls into.


MEX:ASND1N
43GF Score
Ascendis Pharma AS MEX:ASND1N
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ascendis Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ascendis Pharma AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=436.979/122.9500*122.9500
=436.979

Current CPI (Jun. 2026) = 122.9500.

Ascendis Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 64.189 100.200 78.763
201612 118.370 100.300 145.101
201703 95.957 101.200 116.580
201706 80.325 101.200 97.589
201709 119.335 101.800 144.128
201712 118.926 101.300 144.343
201803 187.823 101.700 227.068
201806 182.217 102.300 218.999
201809 157.190 102.400 188.735
201812 149.630 102.100 180.186
201903 332.627 102.900 397.439
201906 310.640 102.900 371.168
201909 297.999 102.900 356.064
201912 263.769 102.900 315.164
202003 294.406 103.300 350.409
202006 256.137 103.200 305.155
202009 461.168 103.500 547.832
202012 380.419 103.400 452.345
202103 358.644 104.300 422.774
202106 301.160 105.000 352.644
202109 415.923 105.800 483.343
202112 362.163 106.600 417.711
202203 267.523 109.900 299.290
202206 229.726 113.600 248.634
202209 159.199 116.400 168.157
202212 97.736 115.900 103.681
202303 58.347 117.300 61.157
202306 21.580 116.400 22.794
202309 -23.895 117.400 -25.025
202312 -48.142 116.700 -50.720
202403 -74.563 118.400 -77.428
202406 -109.737 118.500 -113.858
202409 -35.626 118.900 -36.840
202412 -38.032 118.900 -39.327
202503 -69.477 120.200 -71.067
202506 -68.693 120.700 -69.974
202509 -61.372 121.600 -62.053
202512 -56.014 121.180 -56.832
202603 163.314 121.670 165.032
202606 436.979 122.950 436.979

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS Business Description

Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
43GF Score

Get the complete analysis for MEX:ASND1N

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,424.97
Price